Tuesday, January 17, 2017 1:30:03 AM
Most people relate a co-pay or deductible with a portion of the bill they must cover and the insurance covers the rest. This, basically gives you the ability to get your "medical marijuana" through X, Y or Z and you buy what you want/need. Without a prescription, you cannot do this, that is the beauty of it. A physician is not going to prescribe you Weed A vs Weed B (perhaps in the future maybe but currently no), this genre of medicine is too unique for a physician to do that.
... With that said, just understand this innovative insurance does not work in the traditional way, which is fine, it is pioneering itself into uncharted territory and things are always different in respect to those regards when becoming the first.
I found a video: Novus Medical Alternative & MMJ Health Plan
(this video is also on their front page) http://www.getnovusnow.com
This is a year old but this is kind of the idea around the current Novus outreach. They are improving and getting better this could be the tip of the iceberg. Wall street, bankers, insurance and other skeptics are not currently on board but you can bet their arse they are scratching the surface on contemplating this facet of the market. More time, acceptance, success, research, etc and this could be a big boom. I don't foresee NDEV being a traditional pump and dump penny stock.
However, I am no wizard when it comes to the stock market and have more knowledge of the medical aspect. Perhaps this will stimulate so of your guys' ideas or perceptions of this company and how to go about planning or theorizing what to do or how to do it. I am watching it from certain angles myself but I think this has some potential... It just needs one break.
Godspeed to you investors and this stock NDEV. This genre of the market (marijuana) certainly has intrigued me and it's hard to find which stocks to give any salt to but I think this one is definitely worthy.
Recent NDEV News
- Branded Legacy and Novus Partner to Develop Plant-Based Meds for Health Plans • InvestorsHub NewsWire • 09/12/2023 11:30:00 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM